Vertex Pharmaceuticals's top three insider shareholders as of March 23, 2026 are Reshma Kewalramani (Ceo President, 98.28K shares), Stuart A Arbuckle (Evp, Coo, 63.37K shares), Amit Sachdev (Evp Chief Patient Ext Af Off, 55.57K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Reshma Kewalramani | Ceo President | 98,278 | 0 | 03 Mar, 2026 |
| Stuart A Arbuckle | Evp, Coo | 63,368 | 0 | 02 Jul, 2025 |
| Amit Sachdev | Evp Chief Patient Ext Af Off | 55,570 | 0 | 26 Feb, 2026 |
| Charles F Jr Wagner | Evp, Co Fo | 47,042 | 0 | 26 Feb, 2026 |
| Ourania Tatsis | Evp, Chief Reg. Quality Off. | 46,763 | 0 | 26 Feb, 2026 |
| Bruce I Sachs | 45,000 | 0 | 07 Aug, 2025 | |
| Carmen Bozic | Evp And Cmo | 37,734 | 0 | 03 Mar, 2026 |
| Carmen Bozic | Evp And Cmo | 35,405 | 0 | 17 Mar, 2026 |
| Jeffrey M Leiden | Executive Chairman | 34,797 | 0 | 26 Feb, 2026 |
| David Altshuler | Evp, Chief Scientific Officer | 34,477 | 0 | 26 Jan, 2026 |
| Bastiano Sanna | Evp, Cell Genetic Therapies | 32,038 | 0 | 09 May, 2023 |
| Joy Liu | Evp And Chief Legal Officer | 22,811 | 0 | 04 Mar, 2026 |
| Edward Morrow Iii Atkinson | Evp, Chief Technical Ops. Off. | 18,432 | 0 | 26 Feb, 2026 |
| Duncan Mckechnie | Evp, Chief Commercial Officer | 15,122 | 0 | 06 Mar, 2026 |
| Jonathan Biller | Evp And Chief Legal Officer | 13,659 | 0 | 26 Feb, 2026 |
| Duncan Mckechnie | Evp, Chief Commercial Officer | 12,489 | 0 | 13 Mar, 2026 |
| Mark E. Bunnage | Evp, Chief Scientific Officer | 7,284 | 0 | 26 Feb, 2026 |
| Alan M Garber | 6,872 | 0 | 05 May, 2025 | |
| Kristen Ambrose | Svp Chief Accounting Officer | 6,624 | 0 | 02 Mar, 2026 |
| Terrence C Kearney | 6,536 | 0 | 14 Aug, 2023 | |
| Lloyd Carney | 6,315 | 0 | 20 Nov, 2025 | |
| Lloyd Carney | 6,315 | 0 | 20 Nov, 2025 | |
| Sangeeta N. Bhatia | 4,299 | 0 | 18 Feb, 2026 | |
| Suketu Upadhyay | 2,354 | 0 | 05 May, 2025 | |
| Diana Mckenzie | 2,231 | 0 | 05 May, 2025 | |
| Diana Mckenzie | 2,231 | 0 | 05 May, 2025 | |
| Nancy Thornberry | 2,035 | 0 | 05 May, 2025 | |
| Yuchun Lee | 1,875 | 0 | 31 Jan, 2023 | |
| Jennifer Schneider | 1,718 | 0 | 05 May, 2025 | |
| Michel Lagarde | 1,132 | 0 | 10 Oct, 2023 | |
| Margaret G Mcglynn | 178 | 0 | 03 May, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Mar, 2026 | Carmen Bozic | Common Stock | D | 2,329 | $481.79 | 35,405 | D | S |
| 11 Mar, 2026 | Duncan Mckechnie | Common Stock | D | 2,633 | $498.42 | 12,489 | D | S |
| 04 Mar, 2026 | Duncan Mckechnie | Common Stock | D | 2,437 | $475.30 | 15,122 | D | S |
| 04 Mar, 2026 | Duncan Mckechnie | Common Stock | D | 2,437 | $475.30 | 15,122 | D | S |
| 02 Mar, 2026 | Joy Liu | Common Stock | D | 892 | $495.96 | 22,811 | D | S |
| 27 Feb, 2026 | Carmen Bozic | Common Stock | D | 2,329 | $480.31 | 37,734 | D | S |
| 27 Feb, 2026 | Carmen Bozic | Common Stock | D | 2,329 | $480.31 | 37,734 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 400 | $479.75 | 137,878 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 120 | $481.50 | 137,758 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 240 | $482.84 | 137,518 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 2,510 | $487.13 | 135,008 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 3,278 | $488.27 | 131,730 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 460 | $489.32 | 131,270 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 2,725 | $490.54 | 128,545 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 949 | $491.30 | 127,596 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 2,520 | $493.29 | 125,076 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 3,498 | $494.33 | 121,578 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 15,580 | $495.38 | 105,998 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 5,995 | $496.16 | 100,003 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 1,725 | $496.95 | 98,278 | D | S |